Farma

Shotgun
05.12.2018 kl 11:54 3814

The SER150 clinical data were presented and discussed with nephrology experts. In the short-term clinical study (28 days) in patients diagnosed with Type 2 Diabetes, SER150 was safe and well tolerated. SER150 significantly decreased the urinary albumin-to-creatinine ratio (uACR) in patients with micro-and macro-albuminuria.

http://www.serodus.com/News/2018/SER150-clinical-data

SER150 was safe and caused no tolerability issues. SER150
did not cause any prolongation of the bleeding time. Baseline
values were all comparable between treatment groups and
were unaffected during treatment and after treatment.
SER150 administration significantly shifted T2D patients ACR
to a lower level. After the 4-weeks treatment, almost half
(45%) of patients with macro-albuminuria were diagnosed as
having micro-albuminuria.

Etter kun 4 uker. Sinnsykt!!! Kapsler som inntas oralt, enklere blir det ikke. Det liker Big-pharma!

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.